Long-term safety and efficacy of deferasirox (Exjade®) for up to 5 years in transfusional iron-overloaded patients with sickle cell disease

To date, there is a lack of long-term safety and efficacy data for iron chelation therapy in transfusion-dependent patients with sickle cell disease (SCD). To evaluate the long-term safety and efficacy of deferasirox (a once-daily oral iron chelator), patients with SCD completing a 1-year, Phase II,...

Cijeli opis

Spremljeno u:
Bibliografski detalji
Glavni autori: Vichinsky, Elliott, Bernaudin, Françoise, Forni, Gian Luca, Gardner, Renee, Hassell, Kathryn, Heeney, Matthew M, Inusa, Baba, Kutlar, Abdullah, Lane, Peter, Mathias, Liesl, Porter, John, Tebbi, Cameron, Wilson, Felicia, Griffel, Louis, Deng, Wei, Giannone, Vanessa, Coates, Thomas
Format: Artigo
Jezik:Inglês
Izdano: Blackwell Publishing Ltd 2011
Teme:
Red Cells and Iron
Online pristup:https://ncbi.nlm.nih.gov/pmc/articles/PMC3170481/
https://ncbi.nlm.nih.gov/pubmed/21592110
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1111/j.1365-2141.2011.08720.x
Oznake: Dodaj oznaku
Bez oznaka, Budi prvi tko označuje ovaj zapis!

Similar Items